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Abstract 
Anxiety disorders, namely generalized anxiety disorder, panic disorder, and phobias, are common, 
etiologically complex conditions with a partially genetic basis. Despite differing on diagnostic definitions 
based upon clinical presentation, anxiety disorders likely represent various expressions of an underlying 
common diathesis of abnormal regulation of basic threat-response systems. We conducted genome-
wide association analyses in nine samples of European ancestry from seven large, independent studies. 
To identify genetic variants contributing to genetic susceptibility shared across interview-generated 
DSM-based anxiety disorders, we applied two phenotypic approaches: (1) comparisons between 
categorical anxiety disorder cases and super-normal controls, and (2) quantitative phenotypic factor 
scores derived from a multivariate analysis combining information across the clinical phenotypes. We 
used logistic and linear regression, respectively, to analyze the association between these phenotypes 
and genome-wide single nucleotide polymorphisms. Meta-analysis for each phenotype combined results 
across the nine samples for over 18 000 unrelated individuals. Each meta-analysis identified a different 
genome-wide significant region, with the following markers showing the strongest association: for case-
control contrasts, rs1709393 located in an uncharacterized non-coding RNA locus on chromosomal band 
3q12.3 (P=1.65x10-8); for factor scores, rs1067327 within CAMKMT encoding the calmodulin-lysine N-
methyltransferase on chromosomal band 2p21 (P=2.86x10-9). Independent replication and further 
exploration of these findings are needed to more fully understand the role of these variants in risk and 
expression of anxiety disorders. 
  
Introduction 
Anxiety disorders (ADs), namely generalized anxiety disorder (GAD), panic disorder (PD), and phobias, 
are relatively common, often disabling conditions with lifetime prevalence of over 20%  (Kessler et al, 
2005). Family and twin studies suggest both genetic and environmental factors underlying their etiology, 
with moderate levels of familial aggregation (OR 3-6) and heritability (30-50%) (1). As with most complex 
genetic traits, many linkage and candidate gene association studies of ADs have been conducted, with 
little success in robustly identifying their susceptibility genes (2;3).  
 Genome-wide association studies (GWAS) have proven to be a successful method for the 
identification of common genetic variants that increase susceptibility to complex disease. Recently, 
GWAS of specific anxiety and related disorders such as PD (4;5), post-traumatic stress disorder (6-8), 
obsessive compulsive disorder (9;10), and phobias (11) have been published. However, these have been 
limited by small sample sizes and resulting low overall power to detect significant associations. 
 Despite differing on diagnostic definitions based upon clinical presentation, ADs likely  represent 
various expressions of an underlying common diathesis of abnormal regulation of basic threat-response 
systems (12). ADs exhibit strong lifetime comorbidity with each other (13), with genetic epidemiologic 
studies pointing to shared genetic risk factors between them (14;15). Since clinical descriptions do not 
reflect underlying genetic architecture, traditional studies focused on individual ADs may not represent 
an effective study design for such phenotypes. A more informative approach would coordinate data 
from clusters of disorders with shared genetic risk factors (16). One such strategy is to model a latent 
anxiety liability factor indexing ADs with substantial genetic overlap. Also, for common disorders like 
ADs, disease states can be interpreted as extremes of continuous liability dimensions, as has been done 
for somatic illnesses like obesity and hypertension. Therefore, quantitative trait approaches, assuming a 
continuous liability distribution, can be used to construct informative latent psychiatric phenotypes (17). 
Analyzing AD phenotypes in a coordinated manner may represent a powerful approach for identifying 
susceptibility genes for ADs. This strategy has yielded some success, as demonstrated by prior reports 
from our group (18). 
In the current study, we conducted genome-wide association analyses in nine large, 
independent samples. To identify genetic variants contributing to genetic susceptibility shared across 
the ADs, we applied two phenotypic approaches: (1) categorical case-control comparisons based upon 
having any AD diagnosis, and (2) quantitative phenotypic factor scores derived from a multivariate 
analysis combining information across the clinical phenotypes. We performed a meta-analysis for each 
phenotype across the nine samples for over 18 000 unrelated individuals using around 6.5 million 
imputed SNPs. This represents the largest genetic study to date of any of the ADs and the first of this 
magnitude to explicitly incorporate comorbidity structure directly into prediction of SNP effects. 
 
Materials and Methods 
Overview 
We conducted parallel GWAS in nine samples of European ancestry and combined the results via meta-
analysis.  We applied two phenotypic strategies aimed at capturing common (pleiotropic) genetic effects 
shared across the five core ADs: GAD, PD, social phobia, agoraphobia, and specific phobias. We 
conducted two types of analyses in each sample based upon complementary approaches to modeling 
the comorbidity and common genetic risk across the ADs: (1) case-control (CC) comparisons, in which 
cases were designated as having “any AD” versus supernormal controls, and (2) quantitative factor 
scores (FS) estimated for every subject in the sample using confirmatory factor analysis.  
 
Samples 
Nine samples containing AD phenotypes from seven independent studies participating in the Anxiety 
NeuroGenetics STudy (ANGST) Consortium were included in the meta-analysis. Standardized assessment 
instruments were used to generate DSM-based AD diagnoses, with some exceptions. The samples were 
genotyped on various SNP arrays according to their original study designs. Genotype calling, quality 
control (QC), imputation, and association analyses were performed at each site under similar standard 
protocols. SNP imputation was conducted within each sample using IMPUTE2 (19) or MACH (20) 
software utilizing the full 1000 Genomes Project reference data (March 2012, release v3). Genomic 
locations were based on NCBI build 37/UCSC hg 19 data. After imputation, SNPs with MAF<0.01, poor 
imputation quality <0.30, and Hardy-Weinberg equilibrium p-value <10-6 were removed. See Supplement 
for study descriptions and Supplemental Table S1 for details of genotyping and QC procedures. Table 1 
summarizes basic statistics by cohort.  
 
Genome-wide association analyses 
To identify genetic variants contributing to genetic susceptibility shared across the ADs, we applied and 
compared two complementary phenotypic approaches: (1) categorical CC comparisons, and (2) 
quantitative phenotypic FS. For CC comparisons, AD cases were assigned to subjects meeting criteria for 
any lifetime AD (ANX=2) while control subjects were “super-normal”, i.e., having few or no clinical 
anxiety symptoms (ANX=0); those with subsyndromal ADs (ANX=1) were excluded from the CC analyses. 
For FS analyses, first exploratory factor analyses were conducted using Mplus (version 4) (39) separately 
in each sample, finding evidence for a single common factor model by scree plots. This was followed by 
confirmatory factor analyses that estimated a single FS for each subject from this common AD liability 
factor. (See Supplement for details of phenotype construction.) Association analyses were then 
performed in each study independently with imputed SNP dosages under an additive genetic model 
using logistic regression for CC phenotype and linear regression for quantitative FS phenotype. As 
covariates, we used sex and age at interview, as they were significant predictors of the phenotypes. 
Ancestry principal components were estimated for each sample and included on a sample-by-sample 
basis depending on their correlation with the outcome phenotypes. The quantile-quantile (Q-Q) plot 
was used to evaluate overall significance of the association test results and the genomic control factor λ.  
 
Meta-analysis of GWAS 
We performed an inverse-variance weighted, fixed-effects meta-analysis with all GWAS samples using 
METAL (21) (nine samples using CC phenotypes and eight using FS phenotypes). For each SNP, a pooled 
effect size, standard error, and p-value were computed. SNPs with low MAF (<0.05) were excluded, 
resulting in a final meta-analytic data set of around 6.5M SNPs. Cochran’s Q statistics and corresponding 
I2 statistics were used as heterogeneity metrics. Cochran’s Q statistic was computed by summing the 
squared deviations of each study’s estimate by weighting each study’s contribution in the same manner 
as in the meta-analyses. I2 measured the amount of heterogeneity that is not due to chance.  
Q-Q and Manhattan plots were examined, and False Discovery Rate (FDR) q-values were 
calculated based on the p-values from the meta-analyses. Q-values provide a balance between type I 
and Type II errors and can be interpreted as the probability that a marker identified as significant is a 
false discovery (22).    
 
Cross-validation 
In order to examine overall consistency of association between datasets, we employed a leave-one-out 
procedure for internal cross-validation. At each step, we meta-analyzed eight of the nine CC GWAS 
samples as the “training” set (seven of the eight samples were used for FS), the results of which were 
then tested in the respective remaining target sample (“testing” set). The top associated SNPs in the 
training set (Ptraining<1x10-5, pruned to r2<0.4 within a 500-kb window) were used to test the replicability 
(Ptesting<0.05) and consistency of the direction of their effects with the top associated SNPs identified in 
each testing set. One thousand random permutations of phenotype allocation to an individual’s 
genome-wide genotypes were performed in each training-testing set pair, totaling 9,000 and 8,000 
permutations in CC and FS, respectively.  Across all sets, we compared the aggregate numbers of 
replicated SNPs and SNPs with the same direction of effect against the numbers expected by chance.   
 
Gene-based tests 
The SNP-based p-values derived from the meta-analyses were applied to gene-based association testing 
using KGG software (http://statgenpro.psychiatry.hku.hk/limx/kgg/) (23). No prioritization or pre-
selection of genes was performed. Gene-based tests in KGG combine univariate association statistics to 
evaluate the cumulative evidence of association in a gene using extended Simes test (GATES) (24). SNPs 
were mapped onto 23 931 genes according to the gene coordinate information from NCBI, and SNPs 
within 10-kb of each gene were assigned to that gene. We considered genes with P<2x10-6 (=.05/23 931) 
as significant and those with q-value <0.1 as interesting (25). 
 
Secondary Analyses 
We conducted several secondary analyses, the details of which are described in the Supplement. 
1. SNP-based Heritability. Genomic-relatedness-matrix restricted maximum likelihood (GREML), as 
implemented in the software program GCTA (26), was conducted in our largest cohort (RS) to estimate 
the total amount of variance explained by all analyzed SNPs. This was supplemented by a similar 
procedure in the full meta-analytic sample using LD score regression (27). 
2. Polygenic Risk Profile Analyses. Given the observed high comorbidity between ADs and other 
psychiatric syndromes, genomic profile risk scores (GPRS) (28) were estimated to test the additive joint 
effects of multiple variants between our AD GWAS data as target samples and summary data from 
Psychiatric Genomics Consortium phase 1 (PGC1) schizophrenia (SCZ), bipolar disorder (BIP), and MDD 
as discovery samples. 
RESULTS 
GWAS Meta-analysis 
We performed an inverse-variance weighted, fixed-effects meta-analysis with all discovery GWAS data 
including approximately 6.5M common SNPs after applying post-imputation QC to each study. The 
genomic inflation factor λ ranged from 0.990 to 1.038 for all studies. The Q-Q plots of the meta-analyses 
for the CC and FS phenotypes are presented in Figure 1. Meta-analytic inflation factors were 1.03 and 
1.02, suggesting little effect of population stratification. Manhattan plots are presented in Figure 2. 
Table 2 lists the LD-independent, genome-wide significant SNPs and associated regions. For the CC 
model, the strongest association was observed at rs1709393 located in an intron of an uncharacterized 
non-coding RNA locus LOC152225 on chromosome 3q12.3 (P=1.65x10-8; Q=0.027). Allelic frequencies 
were very similar across studies and ranged between 0.55 and 0.60.  The most significant SNP in the FS 
model was rs1067327 on chromosome 2p21 within CAMKMT encoding the calmodulin-lysine N-
methyltransferase (P=2.86x10-9; Q=0.0017) with LD extending into several adjacent genes. Allelic 
frequencies were consistent across studies, ranging from 0.32 to 0.36. Both of these SNPs were imputed 
with very high quality across studies (R2>0.93). As indicted in the forest plots (Supplementary Figure S1), 
no heterogeneity of effects was observed for either SNP. Figure 3 displays the regional SNP plots for 
these two genome-wide significant loci. 
 Given that the CC and FS phenotypic approaches provide conceptually different but otherwise 
complementary information, we estimated the overlap in their association signals. These phenotypes 
were highly correlated in the different cohorts (0.88-0.94). Overall rank-based correlations between the 
CC and FS association effects were 0.61. The degree of correlation increased with decreasing p-value 
threshold, ranging from 0.275 to 0.899 (Supplementary Table S3).  The most significant SNPs all have the 
same direction of effect (top 1,000 SNPs in CC and top 1,500 SNPs in FS); indeed, among the 
approximately 30% of total SNPs with opposite sign, none had even suggestively significant association 
(P<1x10-5). However, among ~1.4M independent SNPS (pruned at r2=0.4), significantly more with P<10-5 
were identified for the FS phenotype than for the CC phenotype: 42 verses 18 (test p-value=0.0034).  
  
Cross-Validation 
In the leave-one-out cross-validation analyses, the replication rate was significantly higher than 
expected by chance (Table 3). In CC, 18 of 173 tested SNPs across all leave-one out analyses replicated in 
the left out testing sets (permutation P=0.001) and the proportion of SNPs with the same direction of 
effect was 59.5% (sign test P=0.005). Of 315 tested SNPs in FS, 43 SNPs replicated (permutation P<0.001) 
and 77.8% had the same direction of effect (sign test P<0.001). Supplemental Figure S2 displays 
Manhattan plots of the training set meta-analyses conducted after leaving out each sample. 
 
Gene-based tests 
In the CC model, LOC152225 on 3q12.3 surpassed genome-wide significance (P=1.19x10-6; Q=0.028). In 
the FS model, three genes exceeded genome-wide significance: PREPL, CAMKMT, and SLC3A1 on 
chromosome 2 (Table 4). Supplementary Figure S3 depicts the Manhattan plots for these gene-based 
analyses.   
 
Secondary Analyses (see Supplement for details)    
1. SNP-based heritability. This was estimated by GREML using GCTA in the Rotterdam sample as 0.106 
(SE=0.06, P=0.05) for FS phenotype and 0.138 (SE=0.18, P=0.2) for CC phenotype on the liability scale 
assuming 10% AD population prevalence. Within the margin of error, these were consistent with LD 
score regression using summary statistics in the full meta-analysis sample, with SNP heritability 
estimated as 0.072 (SE=0.028) for FS phenotype and 0.095 (SE =0.037) for CC phenotype.  
2. Polygenic Risk Profile Analyses. GPRS from PGC-MDD explained a small but significant proportion of 
variance in CC ADs in QIMR (0.5%-0.7%), while SCZ and BIP each explained a somewhat smaller 
proportion of this variance varying by sample. These results were supported by LD score regression 
performed in the meta-analysis sample, estimating significant genetic correlation between ADs and 
MDD (r=0.68) but not between ADs and BIP or SCZ.  
 
DISCUSSION 
We conducted the largest and most comprehensive genetic study of the primary anxiety disorders (ADs) 
to date. Specifically, we integrated phenotypic information on GAD, PD, agoraphobia, social phobia, and 
specific phobias and combined this with genome-wide SNP data from nine large samples totaling over 
18 000 subjects. We conducted parallel GWAS in these samples and statistically combined the results via 
meta-analysis, with the aim of detecting common variants that play a role in shared AD susceptibility.  
 While only an approximate representation of the underlying complexity of AD genetic 
mechanisms, our integrated phenotypic approaches successfully identified novel genetic variants that 
significantly associate with these composite AD phenotypes. The results were generally the same 
whether analyzing individual SNPs or genes. In the CC model, we identified a novel genome-wide 
association within an uncharacterized non-coding RNA locus LOC152225 on chromosome 3q12.3. We 
found no extant reports for this locus in PubMed or the NHGRI Catalogue of Published GWAS 
(www.genome.gov/gwastudies/). In the FS model, we detected genome-wide significant associations at 
SNPs in three genes within a large LD block on chromosome 2p21, each of which has reported 
expression in brain: (1) SLC3A1 encoding the large subunit of a heterodimeric dibasic /neutral amino 
acid transporter (solute carrier family 3 (amino acid transporter heavy chain), member 1); (2) PREPL 
encoding a putative prolyl endopeptidase belonging to the prolyl oligopeptidase family; and (3) 
CAMKMT encoding a calmodulin-lysine N-methyltransferase. This region is well-known for two 
contiguous gene-deletion syndromes, the hypotonia-cystinuria syndrome and the more severe 2p21 
deletion syndrome (29). Deletion of SLC3A1 results in the autosomal-recessive form of cystinuria (30), 
while  PREPL deletion causes hypotonia at birth, failure to thrive and growth hormone deficiency (31). 
The evolutionarily conserved class I protein methyltransferase encoded by CAMKMT acts in the 
formation of trimethyllysine in calmodulin which is involved in calcium-dependent signaling (32). 
Interestingly, GWAS of schizophrenia and bipolar disorder have highlighted other genes encoding 
proteins involved in calcium-dependent signaling (33).  Although the most significant SNP, rs1067327, is 
located in an intron of CAMKMT , in silico analyses (Supplement) suggest rs698775 is the most likely 
functional candidate with a cis regulatory effect possibly specific to PREPL.  
 There is substantial phenotypic overlap between the CC and FS models used to capture the 
comorbidity and shared genetic risk among the ADs, and as expected, there was a high degree of 
concordance in the association signals genome-wide (Supplementary Table S3). The most significantly 
associated SNPs (p<.0.05) have very high correlation of association effects, suggesting they are tapping 
into strongly related AD risk factors. We note that, overall, the FS phenotype identified a larger number 
of associated SNPs than the CC model. This is likely due to several reasons: (1) this approach combines 
disorder information to capture individual differences on an underlying latent AD liability; (2) for high 
prevalence disorders, quantitative variables generally have greater power for genetic association than 
categorical variables (34;35); (3) the FS models generally involve larger sample sizes since they also 
include the subjects with subthreshold ADs (score=1); and (4) the FS model produces a phenotype that 
incorporates the observed relationship information (covariance) between the individual ADs. These 
findings support the use of quantitative phenotypic factors scores in future GWAS of comorbid 
psychiatric disorders assessed in the same individuals. 
 Several secondary analyses support our findings. First, we applied cross validation in the nine 
samples to examine the internal consistency of the results. We created sub-samples by iteratively 
removing the data of each of the individual samples and conducting meta-analysis with the remaining 
datasets. A highly significant proportion of the top results were consistently identified across these sub-
analyses, suggesting the stability and validity of our findings. Next we estimated the genome-wide 
contribution via GREML and the complementary LD-score regression approach, producing generally 
consistent estimates of SNP heritability across samples included and methods applied. Similar to GWAS 
studies of many phenotypes (36), these estimates are substantially smaller than those predicted by twin 
studies of ADs. Finally, we tested the polygenic association between our results and those from other 
psychiatric disorders using GRPS, finding significant correlation of genetic risk between ADs and MDD 
but not between ADs and BIP or SCZ.  The former result is consistent with large epidemiologic studies 
that report correlated genetic risk between ADs and MDD (see (15) for review) as well as a prior overlap 
seen for depression and anxiety scales (37).  
 A strength of this study is that we applied phenotypic strategies aimed at detecting genetic 
variants that play a central but non-specific role in AD susceptibility. This is counter to the approach 
taken in most psychiatric genetic studies which generally apply case-control comparisons for specific 
clinical diagnoses, sometimes followed by adjunct cross-disorder analyses. However, it has long been 
recognized that clinical nosology poorly reflects etiological mechanisms, with both genetic and 
environmental risk factors showing non-specific effects across disorders.  ADs, despite their 
heterogeneous clinical presentations, likely represent various expressions of an underlying common 
diathesis of abnormal regulation of basic threat-response systems (12). Given the value of fear and 
anxiety for survival, there are likely sets of evolutionarily-conserved genes that regulate these basic 
biological responses. This is supported by twin studies that identify factors of common genetic risk 
across ADs in addition to disorder-specific genetic factors. With this in mind, we applied and compared 
two strategies for combining information across clinical phenotypes. The first is a simple CC approach, 
comparing cases defined as having “any AD” against supernormal controls. The second applied 
multivariate modeling of the covariation among the ADs using the common factor model to define a 
single continuous dimension of liability for which quantitative scores can be estimated for each subject. 
Our group has applied this approach in prior candidate gene association studies (18) and in a pilot GWAS 
in the MGS sample (38), but this is the first such application in a large GWAS meta-analysis. We note 
that this strategy is consistent with NIMH’s Research Domain Criteria (RDoC) initiative, which aims to 
serve as a framework for new approaches to research on mental disorders based on fundamental 
dimensions that cut across traditional disorder categories and more closely align with mechanisms that 
underlie psychopathology at various biological levels from genes to neural circuits (39). Also important 
to note is that ADs not only share genetic risk factors amongst themselves but also with other 
internalizing phenotypes like MDD (15), obsessive compulsive disorder (40), and personality traits like 
neuroticism and extroversion (41). It will be important for future studies to examine this broader 
pleiotropic spectrum either through cross-disorder GWAS as previously conducted for other psychiatric 
conditions (42) or by including these additional traits directly in the phenotypic construction with the 
ADs. It is possible that, by including AD cases with comorbid MDD, the genetic overlap between these 
conditions has influenced our results. 
 Several potential limitations of this study should be noted. First, although the total sample size 
far exceeds those from prior AD genetic studies, it is still relatively underpowered to detect common 
genetic variants of small effect expected for the genetic architecture of such complex phenotypes (37).  
Second, not all samples provided the same level of phenotypic coverage; in particular, some subjects in 
QIMR were missing diagnostic data for GAD or specific phobia. While this can produce bias, our forest 
plots, tests for heterogeneity, and internal validation analyses suggest that this likely did not bias our 
results. Third, consent agreements for some of the sites did not allow for sharing of subject data, so 
GWAS analyses had to be conducted separately using a standardized procedure and combined via meta-
analysis. While this has been shown to approximate the power obtained when using raw data via mega-
analysis (38), we were limited in our ability to conduct additional post-hoc analyses such as GPRS and 
GREML that require the use of raw GWAS data. Reassuringly, results obtained by applying LD score 
regression to summary statistics from the total meta-analysis sample were consistent with those using 
raw data from select individual samples. Fourth, the results apply only to subjects of European-ancestry 
and might not generalize to individuals of other genetic and cultural backgrounds.  Finally, we combined 
all data available at the time of this study into a single meta-analysis rather than divide into discovery 
and replication samples. This was necessary due to the large sample sizes required to detect small 
effects of genes involved in complex traits like ADs. Internal cross-validation supported the robustness 
of our results but do not substitute for replication in well-powered, independent samples. At this time, 
we are unaware of other large data sets that could be used for replication of our results. 
 In summary, this study has identified several potentially novel susceptibility loci that increase 
shared risk across the primary ADs.  Future studies are needed to (1) further confirm these findings via 
independent replication, (2) increase the total sample size to enhance power to detect additional loci, 
and (3) identify loci associated specifically with each particular AD not accounted for by the pleiotropic 
effects targeted in this study. 
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 Table 1. Contributing Cohorts 
Cohort Country 
Mean age (s.d.) 
at interview  
N 
Phenotyped 
N Cases 
(ANX=2) 
N Controls 
(ANX=0) 
N Analyzed 
(FS/CC) 
MGS Controls (43) USA 50.0 (16.4) 2659 757 1059 2009/1336 
PsyCoLaus (44) Switzerland 50.9 (8.8) 3575 1044 1351 2887/1955 
RS (45) Netherlands 66.5 (10.8) 9686 1112 5459 7832/5379 
SHIP(46) Germany 55.4 (13.9) 2279 581 890 2026/1379 
QIMR (47) Australia 41.3 (11.5) 6147 1611 2544 2277/2156 
TRAILS (48) Netherlands 18.7 (0.7) 1584 390 472 1155/614 
NESDA (49) / 
NTR (50;51) 
Netherlands 
45.6 (14.2) / 
  44.6 (12.7) 
4491 1521 2970 NA/4491 
Total   31 060 7016 14 745 
18 186/ 
17 310 
 
Abbreviations: MGS, Molecular Genetics of Schizophrenia; RS, Rotterdam Study; SHIP, Study of Health in 
Pomerania; NESDA/NTR, The Netherlands Study of Depression and Anxiety / Netherlands Twin Registry; 
QIMR, Queensland Institute of Medical Research; TRAILS, Tracking Adolescents' Individual Lives Survey; 
FS, Factor Score; CC, Case-Control. 
 
Table 2. Top association results for meta-analysis of SNP main effects for case-control and factor score 
phenotypes. 
     Association with Original Phenotype  
Cross 
Phenotype† 
SNP A12a Frqmean Chr Positionb Effectc (95% CI) 
p-
value 
q-
value Directiond  p-value Effectc 
Case-Control        
rs1709393 TC 0.58 3 101684480-
101692234 
0.860 (0.816-
0.906) 
1.65e-
8 
0.027 ---------  0.0342 -0.010 
Factor Score        
rs1067327 CG 0.34 2 44588941-44678648 0.028 (0.019-
0.038)  
2.86e-
9 
0.0017 ++++++++  0.0002 1.123 
 
 Chr, chromosome; Frq, frequency of allele 1; CI, 95% confidence interval. 
a First allele is the reference allele, for which the effect is reported. 
b Position denotes the associated region surrounding the top SNP containing 1 or more genome-wide significant 
SNPs in LD (r2>0.4) with the top SNP. 
c Effect size represents odds ratio for case control and regression coefficient for factor score. 
d Direction of association is provided for each study in the following order: RS1, RS2, RS3, NTR/NESDA, MGS, 
PsyColaus, SHIP, QIMR, and TRAILS for case-control; RS1, RS2, RS3, MGS, PsyColaus, SHIP, QIMR, and TRAILS for 
factor score. Plus (+) indicates the association between the SNP and the corresponding anxiety phenotype is 
positive. Minus (-) indicates a negative direction of association.  
† Shown are the association results of the top SNPs in the other phenotype, i.e., factor score results of rs1709393 
and case-control results of rs1067327.  
 
 
  
Table 3. Results of leave-one-out cross-validation analyses 
 Case-Control  Factor Score 
Testing 
Sample 
NSNPa 
Ptraining<10-5 
NSNPb 
Ptesting<0.05 
NSNP 
(same direction) 
 NSNPa 
Ptraining<10-5 
NSNPb 
Ptesting<0.05 
NSNP 
(same direction) 
MGS 19 3 10  39 0 25 
GSK 26 3 12  22 4 11 
RS1 24 0 13  42 6 36 
RS2 15 3 9  45 0 33 
RSs3 22 0 10  46 21 35 
SHIP 24 0 14  40 10 32 
NTR/NESDAc 14 3 13  - - - 
QIMR 13 3 9  35 0 32 
TRAILS 16 3 13  46 2 41 
OVERALL 173 18* (P=0.001) 
103* 
(P=0.005) 
 315 43* (P<0.001) 
245* 
(P<0.001) 
 
*P<0.05 thresholds applied for replication and sign tests; Replication and sign tests are conducted based on 
permutations with 9,000 iterations in case-control and 8,000 iterations in factor score phenotype under the null 
hypothesis of no association (1,000 iteration for each pair of training and testing sets). 
a The number of SNPs associated at Ptraining<1x10¯⁵ with r2<0.4 in the leave-one-out meta-analysis using N-1 
training samples after removing one testing sample at a time. 
b Of the SNPs with Ptraining<1x10¯⁵ in the meta-analysis of the N-1 training samples, the number of replicated 
SNPs with one-sided Ptesting<0.05 in the left-out (testing) sample. 
c Only case-control phenotype is available for NTR/NESDA sample. 
 
  
Table 4. Top associated genes (Q < 0.1) using gene-based tests 
Gene p-valuea q-value SNPb with 
lowest P 
Lowest Pc Chr Gene Feature 
Case-Control       
LOC152225 1.19E-06 0.028 rs1709393 1.65E-08 3 ncRNA 
       
Factor Score       
PREPL 5.61E-08 0.001 rs786618 6.99E-09 2 intronic 
CAMKMT 3.15E-07 0.004 rs1067327 2.86E-09 2 intronic 
SLC3A1 1.45E-06 0.012 rs1142523 1.44E-07 2 3’UTR 
LBX1 7.50E-06 0.045 rs11190870 9.79E-07 10 downstream 
LBX1-AS1 1.33E-05 0.064 rs594791 1.05E-06 10 upstream 
 
We used LD pruning at r2 of 0.4 for gene-based tests. Boldface indicates genome-wide P < 2x10-6. 
a Gene-based p-value (bolded genome-wide significant P<2x10-6) . 
b Most significant SNP within the corresponding gene. 
c SNP-based p-value for the most significant SNP  
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Figure Legends 
Figure 1. Quantile-quantile plots of meta-analysis results for (a) case-control and (b) factor score 
phenotypes. Observed association results of –log10P , after LD-pruning at r2 of 0.4, are plotted against 
the expected distribution under the null hypothesis of no association. 
Figure 2. Manhattan plots of meta-analysis results for (a) case-control and (b) factor score phenotypes. 
Red horizontal line indicates the genome-wide significant p-value 5x10-8; blue line indicates the 
suggestive p-value=1x10-5. 
Fig 3. Regional plots around most significant SNPs in (a) case-control and (b) factor score model. 
 
